• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用定性诊断算法与LI-RADS v2018词典对非典型与典型肝癌病变进行动态肝脏成像的诊断效能:来自一家三级肝脏研究所的十年经验。

Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute.

作者信息

Laroia Shalini Thapar, Yadav Komal, Rastogi Archana, Kumar Guresh, Kumar Senthil, Sarin Shiv Kumar

机构信息

Department of Radiology, Institute of Liver and Biliary Sciences, Sector D-1, Vasant Kunj, New Delhi, 110070, India.

Department of Pathology, Institute of Liver & Biliary Sciences, Sector D-1, Vasant Kunj, New Delhi, 110070, India.

出版信息

Eur J Radiol Open. 2020 Feb 12;7:100219. doi: 10.1016/j.ejro.2020.100219. eCollection 2020.

DOI:10.1016/j.ejro.2020.100219
PMID:32083152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7016378/
Abstract

OBJECTIVE

To analyze and evaluate the diagnostic performance of conventional diagnostic (qualitative) imaging features versus LI-RADSv2018 lexicon for indeterminate and atypical Hepatocellular carcinoma (HCC) on dynamic liver imaging with reference to histopathology.

PATIENTS AND METHODS

This retrospective study (June 2009-June 2019) evaluated the performance characteristics of conventional imaging findings, versus the Liver Imaging Reporting and Data System (LIRADS) v2018, for interpretation of indeterminate and atypical HCC, in patients who underwent subsequent histopathological analysis (gold standard). A total of 100,457 dynamic hepatobiliary CT and MR examinations were performed over ten years at our institute. Using current international imaging guidelines, 3218 patients were found to have suspected liver cancer lesions on imaging. Classical enhancement pattern of typical HCC was seen in 2916 of these patients. These patients did not require further biopsy. We enrolled, the remaining (n = 302) patients, who underwent biopsy, into our study group. Two radiologists, blinded to pathology findings, reviewed and classified these lesions, in consensus, according to LI-RADS® lexicon and as per 'conventional' (Indeterminate, Atypical HCC, Classical HCC, other malignancies) imaging. The histopathology diagnosis was considered as the final diagnosis. Alpha feto protein (AFP) levels amongst various subgroups were compared. Statistical analysis was performed to calculate the efficacy of LIRADS versus qualitative imaging parameters in comparison with histopathology.

RESULTS

A total of n = 302 patients, [89 % men (n = 269), mean age 57.08 ± 12.43 years] underwent biopsy for suspected liver lesions. Qualitative imaging had 92.3 % (CI 88.53-94.91) sensitivity, 41.4 % (CI 25.51-59.26) specificity, positive predictive value (PPV) of 93.7 % (CI 90.11-96.02), negative predictive value (NPV) of 36.4 % (CI 22.19-53.38), positive likelihood ratio (PLHR) of 1.575 (CI 1.40-1.77) and negative likelihood ratio of (NLHR) 0.19 (CI 0.13-0.26). It correctly classified 87.4 % of lesions diagnosed on pathology. In comparison, LI-RADS was found to have 92 % sensitivity, 55.5 % specificity, 97 % PPV, 30.3 %, NPV, PLHR 2.068 (CI 1.62-2.64), NLHR 0.15 (CI 0.11-0.18) and 89.7 % diagnostic accuracy. A total of 38 patients (17 false negative, 21 false positive lesions) had discordant diagnoses on imaging versus histopathology. The kappa agreement between LIRADs and qualitative Imaging was found to be 0.77 ± .07 (p < 0.001). LIRADS and qualitative imaging collectively had 97 % sensitivity, 30 % specificity, 91.9 % PPV, 55.6 % NPV, PLHR of 1.39 (CI 1.27-1.51) and NLHR of 0.09 (0.048-0.19) which was better than, either reporting system, independently.

CONCLUSION

It was observed that the LI-RADS v2018 lexicon with qualitative imaging as a combination technique added extra value in interpretation of atypical HCC or indeterminate lesions on dynamic CT and MRI compared to either as 'stand- alone' reporting systems.

摘要

目的

参照组织病理学,分析和评估传统诊断(定性)成像特征与LI-RADSv2018词典对动态肝脏成像中不确定和非典型肝细胞癌(HCC)的诊断性能。

患者与方法

这项回顾性研究(2009年6月至2019年6月)评估了传统成像结果与肝脏影像报告和数据系统(LIRADS)v2018对不确定和非典型HCC的解读性能特征,这些患者均接受了后续的组织病理学分析(金标准)。在我们研究所的十年间共进行了100457次动态肝胆CT和MR检查。根据当前国际成像指南,在成像检查中发现3218例患者有疑似肝癌病变。其中2916例患者可见典型HCC的经典强化模式。这些患者无需进一步活检。我们将其余(n = 302)接受活检的患者纳入研究组。两名对病理结果不知情的放射科医生根据LI-RADS®词典并按照“传统”(不确定、非典型HCC、经典HCC、其他恶性肿瘤)成像方法,对这些病变进行了一致的复查和分类。组织病理学诊断被视为最终诊断。比较了各亚组中甲胎蛋白(AFP)水平。进行统计分析以计算LIRADS与定性成像参数相对于组织病理学的有效性。

结果

共有n = 302例患者[89%为男性(n = 269),平均年龄57.08±12.43岁]因疑似肝脏病变接受活检。定性成像的敏感性为92.3%(CI 88.53 - 94.91),特异性为41.4%(CI 25.51 - 59.26),阳性预测值(PPV)为93.7%(CI 90.11 - 96.02),阴性预测值(NPV)为36.4%(CI 22.19 - 53.38),阳性似然比(PLHR)为1.575(CI 1.40 - 1.77),阴性似然比(NLHR)为0.19(CI 0.13 - 0.26)。它正确分类了病理诊断的87.4%的病变。相比之下,LI-RADS的敏感性为92%,特异性为55.5%,PPV为97%,NPV为30.3%,PLHR为2.068(CI 1.62 - 2.64),NLHR为0.15(CI 0.11 - 0.18),诊断准确性为89.7%。共有38例患者(17例假阴性、21例假阳性病变)在成像与组织病理学诊断上存在不一致。发现LIRADs与定性成像之间的kappa一致性为0.77±.07(p < 0.001)。LIRADS和定性成像共同的敏感性为97%,特异性为30%,PPV为91.9%,NPV为55.6%,PLHR为1.39(CI 1.27 - 1.51)且NLHR为0.09(0.048 - 0.19),这比任何一种报告系统单独使用时都要好。

结论

观察到与单独作为报告系统相比,LI-RADS v2018词典结合定性成像作为一种联合技术,在动态CT和MRI上对非典型HCC或不确定病变的解读中增加了额外价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/7c483b508704/gr20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/81e65e977993/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/cd784cee5591/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/38c983c9c608/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/fc2c2427a322/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/feb48aae2cec/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/b5883b26e1ce/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/35484bea7f4c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/86f44b90d2d4/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/969fab08e4a7/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/75c57ab4254b/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/47d24f79eb5e/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/d54ca0c29d4e/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/2c52befc6f46/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/90b274e32e0b/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/fdd98f87d650/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/72df7bb05d54/gr16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/4963331c26f1/gr17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/21769fb4107e/gr18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/1bd3b0543d88/gr19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/7c483b508704/gr20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/81e65e977993/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/cd784cee5591/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/38c983c9c608/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/fc2c2427a322/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/feb48aae2cec/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/b5883b26e1ce/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/35484bea7f4c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/86f44b90d2d4/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/969fab08e4a7/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/75c57ab4254b/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/47d24f79eb5e/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/d54ca0c29d4e/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/2c52befc6f46/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/90b274e32e0b/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/fdd98f87d650/gr15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/72df7bb05d54/gr16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/4963331c26f1/gr17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/21769fb4107e/gr18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/1bd3b0543d88/gr19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/7016378/7c483b508704/gr20.jpg

相似文献

1
Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute.使用定性诊断算法与LI-RADS v2018词典对非典型与典型肝癌病变进行动态肝脏成像的诊断效能:来自一家三级肝脏研究所的十年经验。
Eur J Radiol Open. 2020 Feb 12;7:100219. doi: 10.1016/j.ejro.2020.100219. eCollection 2020.
2
Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.基于 LI-RADS v2018 的肝细胞癌的 MRI 诊断性能,与 v2017 相比。
J Magn Reson Imaging. 2019 Sep;50(3):746-755. doi: 10.1002/jmri.26640. Epub 2019 Jan 15.
3
Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.LI-RADS 版本 2018、LI-RADS 版本 2017 和 OPTN 标准用于诊断肝细胞癌的性能比较。
AJR Am J Roentgenol. 2020 Nov;215(5):1085-1092. doi: 10.2214/AJR.20.22772. Epub 2020 Sep 2.
4
Comparative Performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis.2018 年 LI-RADS 与改良版 LI-RADS(mLI-RADS)的比较性能:一项个体参与者数据荟萃分析。
J Magn Reson Imaging. 2024 Sep;60(3):1082-1091. doi: 10.1002/jmri.29167. Epub 2023 Dec 1.
5
Automated CT LI-RADS v2018 scoring of liver observations using machine learning: A multivendor, multicentre retrospective study.使用机器学习对肝脏影像进行自动CT LI-RADS v2018评分:一项多厂商、多中心回顾性研究。
JHEP Rep. 2023 Jul 22;5(10):100857. doi: 10.1016/j.jhepr.2023.100857. eCollection 2023 Oct.
6
Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.肝细胞癌风险患者中非肝细胞癌恶性肿瘤的诊断:对比增强超声LI-RADS与CT/MRI LI-RADS
Front Oncol. 2021 Apr 12;11:641195. doi: 10.3389/fonc.2021.641195. eCollection 2021.
7
Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.肝细胞癌(HCC)与非 HCC:肝脏影像报告和数据系统 v2018 的准确性和可靠性。
Abdom Radiol (NY). 2019 Jun;44(6):2116-2132. doi: 10.1007/s00261-019-01948-x.
8
Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study.LI-RADS v2017 对预测儿童患者恶性肝脏病变的诊断性能:一项初步研究。
Pediatr Radiol. 2019 May;49(6):746-758. doi: 10.1007/s00247-019-04358-9. Epub 2019 May 8.
9
Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?动脉期增强程度和廓清率的定量评估是否能提高基于 LI-RADS v2018 的肝脏病变分类?
Eur Radiol. 2020 May;30(5):2922-2933. doi: 10.1007/s00330-019-06596-9. Epub 2020 Feb 4.
10
Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment.肝细胞癌的放射学诊断并不排除在治疗前进行活检。
JHEP Rep. 2023 Nov 3;6(1):100957. doi: 10.1016/j.jhepr.2023.100957. eCollection 2024 Jan.

引用本文的文献

1
Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.LI-RADS 类别 5 与类别 4 和 5 联合的表现:系统评价和荟萃分析。
Eur Radiol. 2024 Nov;34(11):7025-7040. doi: 10.1007/s00330-024-10813-5. Epub 2024 May 29.
2
Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.优化 LI-RADS:从 LR-3/4 类别筛选出的辅助特征可提高 MRI 对 HCC 的诊断。
BMC Gastroenterol. 2024 Mar 21;24(1):117. doi: 10.1186/s12876-024-03201-2.
3
Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.

本文引用的文献

1
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.用于诊断小肝癌的细胞外和肝胆磁共振造影剂的比较
J Hepatol. 2020 May;72(5):937-945. doi: 10.1016/j.jhep.2019.12.011. Epub 2019 Dec 21.
2
Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience.伴有或不伴有肝硬化的酒精性肝细胞癌生存结局的比较:十年经验
Medicine (Baltimore). 2019 Nov;98(47):e18020. doi: 10.1097/MD.0000000000018020.
3
Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.
肝脏影像报告和数据系统 2018 版第 5 类诊断肝细胞癌:一项更新的荟萃分析。
Eur Radiol. 2024 Mar;34(3):1502-1514. doi: 10.1007/s00330-023-10134-z. Epub 2023 Sep 1.
4
Evaluation of C-reactive protein and fibrinogen in comparison to CEA and CA72-4 as diagnostic biomarkers for colorectal cancer.与癌胚抗原(CEA)和糖类抗原72-4(CA72-4)相比,评估C反应蛋白和纤维蛋白原作为结直肠癌诊断生物标志物的情况。
Heliyon. 2023 May 8;9(5):e16092. doi: 10.1016/j.heliyon.2023.e16092. eCollection 2023 May.
5
Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer.循环 lncRNA UCA1 和 lncRNA PGM5-AS1 可作为早期结直肠癌的潜在诊断生物标志物。
Biosci Rep. 2021 Jul 30;41(7). doi: 10.1042/BSR20211115.
6
Surgical Resection vs. Percutaneous Ablation for Single Hepatocellular Carcinoma: Exploring the Impact of Li-RADS Classification on Oncological Outcomes.单发性肝细胞癌的手术切除与经皮消融治疗:探讨肝脏影像报告和数据系统(Li-RADS)分类对肿瘤学结局的影响
Cancers (Basel). 2021 Apr 1;13(7):1671. doi: 10.3390/cancers13071671.
与单纯肝细胞癌相比,罕见肝细胞癌变异体的临床结局
J Hepatocell Carcinoma. 2019 Jul 22;6:119-129. doi: 10.2147/JHC.S215235. eCollection 2019.
4
Biomarkers imaging in the early detection of hepatocellular carcinoma and prognosis.生物标志物成像在肝细胞癌早期检测及预后中的应用
World J Clin Cases. 2019 Jun 26;7(12):1367-1382. doi: 10.12998/wjcc.v7.i12.1367.
5
LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.LI-RADS 版本 2017 与版本 2018:钆塞酸二钠增强 MRI 诊断肝细胞癌。
Radiology. 2019 Sep;292(3):655-663. doi: 10.1148/radiol.2019182867. Epub 2019 Jul 16.
6
Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.肝细胞癌及其类似物的不典型表现:如何使用钆塞酸增强肝脏磁共振成像解决具有挑战性的病例。
Korean J Radiol. 2019 Jul;20(7):1019-1041. doi: 10.3348/kjr.2018.0636.
7
Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma.血清生物标志物甲胎蛋白、癌胚抗原和糖类抗原19-9联合检测用于肝细胞癌的早期诊断
Iran J Public Health. 2019 Feb;48(2):314-322.
8
Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines.肝胆磁共振对比剂和对比增强超声在肝细胞癌无创诊断中的新作用:重点介绍主要指南中的最新更新。
Korean J Radiol. 2019 Jun;20(6):863-879. doi: 10.3348/kjr.2018.0450.
9
Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?肝癌患者术后预后是否存在性别差异?
BMC Cancer. 2019 Mar 20;19(1):250. doi: 10.1186/s12885-019-5453-3.
10
LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.肝脏影像报告和数据系统(LI-RADS):从其起源到最近纳入美国肝病研究学会(AASLD)临床实践指南的概念与历史回顾
J Hepatocell Carcinoma. 2019 Feb 5;6:49-69. doi: 10.2147/JHC.S186239. eCollection 2019.